Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

BACKGROUND: Studies evaluating the CNS penetration of a novel tyrosine kinase inhibitor, entrectinib, proved challenging, particularly due to discrepancies across earlier experiments regarding P-glycoprotein (P-gp) interaction and brain distribution. To address this question, we used a novel “apical...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Holger, Ullah, Mohammed, de la Cruz, Cecile C, Hunsaker, Thomas, Senn, Claudia, Wirz, Thomas, Wagner, Björn, Draganov, Dragomir, Vazvaei, Faye, Donzelli, Massimiliano, Paehler, Axel, Merchant, Mark, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283026/
https://www.ncbi.nlm.nih.gov/pubmed/32383735
http://dx.doi.org/10.1093/neuonc/noaa052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283026/
https://www.ncbi.nlm.nih.gov/pubmed/32383735
http://dx.doi.org/10.1093/neuonc/noaa052

Ejemplares similares